GenSight Biologics S.A. is a clinical-stage biopharma company, founded in France, focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.

GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence {MTS) and optogenetics, to help preserve or restore vision In patients suffering from blnding retinal diseases. Gen Sight Biologics' lead product candidate, LUMEVOQ• {GS0l0; lenadogene
nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness primarily in teens and young adults. Using gene therapy based approaches, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.